Equities research analysts predict that Ultragenyx Pharmaceutical Inc (NASDAQ:RARE) will announce earnings of ($1.72) per share for the current fiscal quarter, according to Zacks. Three analysts have issued estimates for Ultragenyx Pharmaceutical’s earnings, with the highest EPS estimate coming in at ($1.59) and the lowest estimate coming in at ($1.83). Ultragenyx Pharmaceutical posted earnings per share of ($1.46) during the same quarter last year, which would indicate a negative year over year growth rate of 17.8%. The business is expected to report its next quarterly earnings report on Monday, August 14th.

According to Zacks, analysts expect that Ultragenyx Pharmaceutical will report full year earnings of ($7.01) per share for the current fiscal year, with EPS estimates ranging from ($7.80) to ($6.52). For the next financial year, analysts expect that the company will report earnings of ($6.52) per share, with EPS estimates ranging from ($7.83) to ($5.22). Zacks Investment Research’s EPS calculations are an average based on a survey of research firms that that provide coverage for Ultragenyx Pharmaceutical.

Ultragenyx Pharmaceutical (NASDAQ:RARE) last released its quarterly earnings results on Thursday, May 4th. The biopharmaceutical company reported ($1.63) earnings per share for the quarter, beating the consensus estimate of ($1.71) by $0.08. During the same period in the previous year, the firm posted ($1.35) earnings per share.

Several research analysts have weighed in on the stock. Wedbush lowered shares of Ultragenyx Pharmaceutical from an “outperform” rating to a “neutral” rating and lowered their target price for the stock from $80.00 to $75.00 in a research report on Wednesday, April 19th. Piper Jaffray Companies lowered shares of Ultragenyx Pharmaceutical from an “overweight” rating to a “neutral” rating and lowered their target price for the stock from $96.00 to $70.00 in a research report on Wednesday, March 22nd. SunTrust Banks, Inc. upped their target price on shares of Ultragenyx Pharmaceutical from $100.00 to $105.00 and gave the stock a “buy” rating in a research report on Wednesday, April 19th. HC Wainwright lowered shares of Ultragenyx Pharmaceutical from a “buy” rating to a “neutral” rating and lowered their target price for the stock from $88.00 to $72.00 in a research report on Wednesday, April 19th. Finally, Canaccord Genuity restated a “buy” rating on shares of Ultragenyx Pharmaceutical in a research report on Monday, May 8th. One investment analyst has rated the stock with a sell rating, six have given a hold rating and nine have given a buy rating to the stock. The stock currently has a consensus rating of “Buy” and a consensus target price of $83.00.

TRADEMARK VIOLATION NOTICE: This article was originally reported by American Banking News and is owned by of American Banking News. If you are accessing this article on another website, it was illegally copied and republished in violation of U.S. and international copyright and trademark law. The original version of this article can be accessed at https://www.americanbankingnews.com/2017/05/25/zacks-brokerages-anticipate-ultragenyx-pharmaceutical-inc-rare-to-post-1-72-earnings-per-share.html.

Ultragenyx Pharmaceutical (NASDAQ:RARE) traded up 0.63% during mid-day trading on Thursday, hitting $60.39. The company’s stock had a trading volume of 17,904 shares. Ultragenyx Pharmaceutical has a 52-week low of $46.52 and a 52-week high of $91.35. The stock’s market cap is $2.56 billion. The company’s 50 day moving average is $60.27 and its 200-day moving average is $71.70.

In other news, CFO Shalini Sharp sold 12,000 shares of the stock in a transaction that occurred on Monday, February 27th. The shares were sold at an average price of $80.14, for a total value of $961,680.00. Following the sale, the chief financial officer now directly owns 63,887 shares in the company, valued at $5,119,904.18. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through the SEC website. Also, insider Theodore Alan Huizenga sold 2,500 shares of the stock in a transaction that occurred on Thursday, March 9th. The shares were sold at an average price of $86.34, for a total transaction of $215,850.00. The disclosure for this sale can be found here. Insiders sold 26,500 shares of company stock worth $2,258,730 over the last quarter. Company insiders own 10.10% of the company’s stock.

Hedge funds have recently added to or reduced their stakes in the stock. Fortaleza Asset Management Inc. raised its stake in Ultragenyx Pharmaceutical by 148.5% in the first quarter. Fortaleza Asset Management Inc. now owns 1,640 shares of the biopharmaceutical company’s stock valued at $111,000 after buying an additional 980 shares in the last quarter. Pacer Advisors Inc. raised its stake in Ultragenyx Pharmaceutical by 9.4% in the third quarter. Pacer Advisors Inc. now owns 2,237 shares of the biopharmaceutical company’s stock valued at $159,000 after buying an additional 192 shares in the last quarter. Turner Investments LLC acquired a new stake in Ultragenyx Pharmaceutical during the fourth quarter valued at approximately $176,000. Strs Ohio raised its stake in Ultragenyx Pharmaceutical by 10.7% in the first quarter. Strs Ohio now owns 3,100 shares of the biopharmaceutical company’s stock valued at $210,000 after buying an additional 300 shares in the last quarter. Finally, Ameritas Investment Partners Inc. raised its stake in Ultragenyx Pharmaceutical by 3.7% in the first quarter. Ameritas Investment Partners Inc. now owns 3,226 shares of the biopharmaceutical company’s stock valued at $219,000 after buying an additional 115 shares in the last quarter. Institutional investors and hedge funds own 96.35% of the company’s stock.

Ultragenyx Pharmaceutical Company Profile

Ultragenyx Pharmaceutical Inc is a clinical-stage biopharmaceutical company. The Company is focused on the identification, acquisition, development, and commercialization of products for the treatment of genetic diseases. Its clinical-stage pipeline consists of two product categories: biologics (including a monoclonal antibody and an enzyme replacement therapy), and small-molecule substrate replacement therapies.

12 Month Chart for NASDAQ:RARE

Get a free copy of the Zacks research report on Ultragenyx Pharmaceutical (RARE)

For more information about research offerings from Zacks Investment Research, visit Zacks.com

Receive News & Ratings for Ultragenyx Pharmaceutical Inc Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Ultragenyx Pharmaceutical Inc and related companies with MarketBeat.com's FREE daily email newsletter.